Molecular Characterization of Candida Auris
OC
Formulation Development and In-Vitro Studies of Efficacy of Botanical Extracts Against Candida Auris
1 other identifier
observational
384
1 country
2
Brief Summary
Candida auris is emerging fungal opportunistic pathogen in developing countries. Much studies has been conducted on Candida albicans. there was a dire need to investigate this alarming threat. Our hypothesis is that by recording the patients diagnosed with oropharygneal candidiasis and collecting clinical swab samples from these patients will be fruitful if microbiological isolation, identification and molecular characterization will be done. So this is the first study on C. auris in south punjab, Pakistan. Aim of this study is to collect epidemiological data of C. auris.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2019
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 7, 2019
CompletedFirst Posted
Study publicly available on registry
October 10, 2019
CompletedStudy Start
First participant enrolled
November 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 29, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
February 29, 2020
CompletedOctober 27, 2020
October 1, 2020
4 months
October 7, 2019
October 25, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Prevalence of C. auris
patients from selected localities will be recorded along with total patients in that category, prevalence will be calculated on the record collected from specified duration of study
From November 15, 2019 to February 29, 2020
Seasonality of C. auris infection
Number of patients recorded during different months will be the source of calculation of seasonality index of the C. auris infection
From November 15, 2019 to February 29, 2020
Drug susceptibility
Antifungal drug discs will be used for assessing the antfungal drugs susceptibility
From November 15, 2019 to February 29, 2020
Interventions
Not required
Eligibility Criteria
All individuals are equally eligible to be selected in the study
You may qualify if:
- Pre-diagnosed Patients of both gender from pre-selected localities
You may not qualify if:
- Healthy individuals or individuals having no oral fungal infection individuals above 100 years of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Bahawal Victoria Hospital Bahawalpur
Bahawalpur, Punjab Province, 63100, Pakistan
Civil Hospital Jhangi Wala Road Bahawalpur
Bahawalpur, Punjab Province, 63100, Pakistan
Biospecimen
Clinical oral swab samples from infected patients will be collected
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jafi H Shirazi, M.Phil
The Islamia University of Bahawalpur
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 7, 2019
First Posted
October 10, 2019
Study Start
November 15, 2019
Primary Completion
February 29, 2020
Study Completion
February 29, 2020
Last Updated
October 27, 2020
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will not share
Individual privacy is prime important, hence data will not be shared